4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nuformix plc (NFX) operates in the Biotechnology industry and is headquartered in London, United Kingdom with about 3 employees. Its market capitalization is roughly £4 million. In the fiscal year ended 2025-09-30, NFX reported £0M in revenue and (£1M) in net income.
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.
Interactive charts & full statements →
| Income statement | 2025-09-30 | 2024-09-30 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Total Revenue | £0M | £0M | — | £0M |
| Gross Profit | £0M | £0M | — | £0M |
| Operating Income (EBIT) | (£1M) | (£0M) | — | (£1M) |
| Net Income | (£1M) | (£4M) | — | (£1M) |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-09-30 | 2024-09-30 | 2022-03-31 |
|---|---|---|---|
| Total Assets | £1M | £1M | £5M |
| Total Liabilities | £0M | £0M | £0M |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NFX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms